MCID: ESN011
MIFTS: 45

Eisenmenger Syndrome malady

Categories: Rare diseases, Respiratory diseases

Aliases & Classifications for Eisenmenger Syndrome

About this section
Sources:
31ICD10 via Orphanet, 48NIH Rare Diseases, 50Novoseek, 54Orphanet, 68UMLS
See all MalaCards sources

Aliases & Descriptions for Eisenmenger Syndrome:

Name: Eisenmenger Syndrome 48 54 50
 
Eisenmenger Complex 68

Characteristics:

Orphanet epidemiological data:

54
eisenmenger syndrome:
Inheritance: Not applicable; Prevalence: 1-9/1000000 (Belgium),1-9/1000000 (Europe); Age of onset: Adolescent,Adult,Childhood; Age of death: adult

Classifications:



External Ids:

Orphanet54 ORPHA97214
ICD10 via Orphanet31 I27.2

Summaries for Eisenmenger Syndrome

About this section
NIH Rare Diseases:48 Eisenmenger syndrome is a rare progressive heart condition caused by a structural error in the heart, typically a "hole in the heart" (ventricular septal defect) present at birth (congenital heart defect). this causes abnormal blood flow in the heart, resulting in high pressure within the pulmonary artery, the main blood vessel that connects the heart to the lungs (pulmonary hypertension). last updated: 10/21/2010

MalaCards based summary: Eisenmenger Syndrome, also known as eisenmenger complex, is related to myocardial infarction and urogenital adysplasia. An important gene associated with Eisenmenger Syndrome is THBD (Thrombomodulin), and among its related pathways are NTHi-Induced Signaling and mTOR Pathway. Affiliated tissues include heart, lung and brain, and related mouse phenotypes are normal and embryo.

Related Diseases for Eisenmenger Syndrome

About this section

Diseases related to Eisenmenger Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 75)
idRelated DiseaseScoreTop Affiliating Genes
1myocardial infarction28.6EDN1, PLAT, TGFB1, THBD, VWF
2urogenital adysplasia10.3THBD, VWF
3pulmonary hypertension10.2
4immune-mediated encephalomyelitis10.2THBD, VWF
5heart disease10.2
6ventricular septal defect10.2
7febrile ulceronecrotic mucha-habermann disease10.1TGFBR1, TGFBR2
8infective dermatitis associated with htlv-110.1TGFBR1, TGFBR2
9immunodeficiency 32a, mycobacteriosis, autosomal dominant10.1PLAT, THBD
10metaphyseal chondrodysplasia with cone-shaped epiphyses, normal hair, and normal hands10.1PLAT, THBD
11inflammatory breast carcinoma10.1TGFBR1, TGFBR2
12intellectual developmental disorder with persistence of fetal hemoglobin10.1TGFBR1, TGFBR2
13citrulline transport defect10.1BMPR2, EDN1
14sialadenitis10.1EDN1, THBD, VWF
15neonatal diabetes mellitus10.1EDN1, THBD, VWF
16acute proliferative glomerulonephritis10.0EDN1, THBD, VWF
17secretory diarrhea myopathy and deafness10.0PLAT, VWF
18septic myocarditis10.0PLAT, THBD, VWF
19pregnancy loss, recurrent 110.0PLAT, THBD, VWF
20mucolipidoses10.0EDN1, PLAT
21immunodeficiency, common variable, 610.0PLAT, THBD, VWF
22congenital chloride diarrhea10.0PLAT, THBD, VWF
23bone development disease10.0PLAT, THBD, VWF
24hematocele of tunica vaginalis testis10.0BMPR2, EDN1
25monocular exotropia10.0PLAT, VWF
26patent ductus arteriosus10.0
27ductal carcinoma in situ10.0PLAT, THBD
28budd-chiari syndrome9.9PLAT, THBD, VWF
29adult t-cell leukemia9.9EDN1, PLAT, VWF
30endotheliitis9.9
31basilar artery insufficiency9.9TGFB1, THBD, VWF
32respiratory syncytial virus infectious disease9.9BMPR2, TGFB1, TGFBR1
33pyrimidine metabolic disorder9.8EDN1, PLAT, VWF
34endemic typhus9.8TGFB1, TGFBR1, TGFBR2
35thrombosis9.8
36mass syndrome9.8TGFB1, TGFBR1, TGFBR2
37pericarditis9.8EDN1, PLAT, THBD, VWF
38hypertension, essential9.8EDN1, PLAT, THBD, VWF
39acute closed-angle glaucoma9.8EDN1, TGFB1, TGFBR2
40herpes simplex9.8EDN1, TGFB1, THBD, VWF
41tetralogy of fallot9.7
42paraganglioma9.7
43down syndrome9.7
44vascular disease9.7
45aortopulmonary window9.7
46fiedler's myocarditis9.7BMPR2, EDN1, TGFB1, VWF
47rheumatoid arthritis9.6
48coarctation of aorta9.6
49angina pectoris9.6
50arthritis9.6

Graphical network of the top 20 diseases related to Eisenmenger Syndrome:



Diseases related to eisenmenger syndrome

Symptoms & Phenotypes for Eisenmenger Syndrome

About this section

MGI Mouse Phenotypes related to Eisenmenger Syndrome according to GeneCards Suite gene sharing:

41 (show all 14)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00028738.7BMPR2, EDN1, TGFBR1, TGFBR2, THBD, VIP
2MP:00053808.3BMPR2, EDN1, TGFB1, TGFBR1, TGFBR2, THBD
3MP:00053798.1EDN1, PLAT, TGFB1, TGFBR1, TGFBR2, VIP
4MP:00053817.9EDN1, PLAT, TGFB1, TGFBR1, TGFBR2, THBD
5MP:00053887.7BMPR2, PLAT, TGFB1, TGFBR1, TGFBR2, THBD
6MP:00053697.6BMPR2, EDN1, PLAT, TGFB1, TGFBR1, TGFBR2
7MP:00053847.6BMPR2, PLAT, TGFB1, TGFBR1, TGFBR2, TGFBR3
8MP:00053977.6BMPR2, PLAT, TGFB1, TGFBR1, TGFBR2, TGFBR3
9MP:00036317.3BMPR2, EDN1, PLAT, TGFB1, TGFBR1, TGFBR2
10MP:00053877.1BMPR2, PLAT, TGFB1, TGFBR1, TGFBR2, TGFBR3
11MP:00053767.0BMPR2, EDN1, PLAT, TGFB1, TGFBR1, TGFBR2
12MP:00053906.8BMPR2, EDN1, PLAT, TGFB1, TGFBR1, TGFBR2
13MP:00053856.7BMPR2, EDN1, PLAT, TGFB1, TGFBR1, TGFBR2
14MP:00107686.6BMPR2, EDN1, PLAT, TGFB1, TGFBR1, TGFBR2

Drugs & Therapeutics for Eisenmenger Syndrome

About this section

Drugs for Eisenmenger Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 30)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
Iloprostapproved, investigationalPhase 47978919-13-86443959
Synonyms:
(16R,S)-Methyl-18,18,19,19-tetradehydro-6a-carbaprostaglandin I(sub 2)
(5E)-5-[(3aS,4R,5R,6aS)-5-hydroxy-4-[(E,3S)-3-hydroxy-4-methyloct-1-en-6-ynyl]-3,3a,4,5,6,6a-hexahydro-1H-pentalen-2-ylidene]pentanoic acid
(5E)-5-[(3aS,5R,6aS)-5-hydroxy-4-[(1E,3S)-3-hydroxy-4-methyloct-1-en-6-yn-1-yl]hexahydropentalen-2(1H)-ylidene]pentanoic acid
(5E)-5-[(3aS,5R,6aS)-5-hydroxy-4-[(E,3S)-3-hydroxy-4-methyloct-1-en-6-ynyl]-3,3a,4,5,6,6a-hexahydro-1H-pentalen-2-ylidene]pentanoic acid
(5Z)-5-[(3aS,5R,6aS)-5-hydroxy-4-[(E,3R)-3-hydroxy-4-methyloct-1-en-6-ynyl]-3,3a,4,5,6,6a-hexahydro-1H-pentalen-2-ylidene]pentanoic acid
(E)-(3aS,4R,5R,6aS)-Hexahydro-5-hydroxy-4-((E)-(3S,4RS)-3-hydroxy-4-methyl-1-octen-6-ynyl)-delta(sup 2(1H),delta)-pentalenevaleric acid
(E)-5-(3aS,4R,5R,6aS)-5-Hydroxy-4((E)-(3S,4RS)-3-hydroxy-4-methyl-1-octen-6-inyl)perhydropentalen-2-yliden)valeriansaeure
73873-87-7
78919-13-8
AC1NSK5T
AC1O5JIJ
AC1O5JP3
AC1Q1J28
ACT-213105
C22H32O4
CHEMBL138694
CHEMBL236025
CHEMBL494
CID10937300
CID11639089
CID5311181
CID6435293
CID6435378
CID9885245
 
CID9975807
Ciloprost
D02721
E-1030
Endoprost
HMS2090A19
ILOPROST
Ilomedin
Ilomedine
Iloprost
Iloprost (INN)
Iloprost [BAN:INN]
Iloprostum
Iloprostum [Latin]
L000996
LS-101845
NCGC00181784-01
PDSP2_001536
SH-401
UNII-JED5K35YGL
Ventavis
Ventavis (TN)
ZK 36374
ZK-36374
ZK-363775
[3H]-Iloprost
2
Bosentanapproved, investigationalPhase 4, Phase 3104147536-97-8104865
Synonyms:
-5-(o-methoxyphenoxy)-2-(2-pyrimidinyl)-4-pyrimidinyl]benzenesulfonamide
147536-97-8
174227-18-0
4-(1,1-Dimethylethyl)-N-(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-(2,2'-bipyrimidin)-4-yl) benzenesulfornamide
4-(1,1-Dimethylethyl)-N-(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-(2,2'-bipyrimidin)-4-yl)benzenesulfornamide
4-t-butyl-N-(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2,2'-bipyrimidin-4-yl)benzenesulfonamide
4-tert-butyl-N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2,2'-bipyrimidin-4-yl]benzenesulfonamide
4-tert-butyl-N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-pyrimidin-2-ylpyrimidin-4-yl]benzenesulfonamide
AC-148
AC1L2XN2
Actelion
Bosentan
Bosentan (INN)
Bosentan [USAN:INN:BAN]
Bosentan hydrate
C27H29N5O6S
CHEBI:51450
CHEMBL957
CID104865
D07538
DB00559
 
EN002863
HMS2090N14
I06-1873
KS-5062
L001086
LS-31532
MolPort-003-845-300
NCGC00167440-01
PDSP1_001731
PDSP2_001714
Ro 47-0203
Ro 47-0203/039
Ro-47-0203
Ro-47-0203/029
Ro-47-0203/039
TL8001039
Tracleer
UNII-XUL93R30K2
bosentan
bosentanum
bosentán
p-tert-Butyl-N-(6-(2-hydroxyethoxy)-5-(o-methoxyphenoxy)-2-(2-pyrimidinyl)-4-pyrimidinyl)benzenesulfonamide
p-tert-Butyl-N-[6-(2-hydroxyethoxy)
3Platelet Aggregation InhibitorsPhase 4, Phase 1, Phase 22516
4Vasodilator AgentsPhase 4, Phase 3, Phase 2, Phase 13543
5Endothelin Receptor AntagonistsPhase 4, Phase 3218
6Antihypertensive AgentsPhase 4, Phase 34207
7
MacitentanapprovedPhase 336441798-33-0
Synonyms:
 
Macitentanum
8Sildenafil CitratePhase 3, Phase 1, Phase 2331171599-83-0
9Phosphodiesterase InhibitorsPhase 3, Phase 2, Phase 11289
10Phosphodiesterase 5 InhibitorsPhase 3, Phase 2, Phase 1589
11Endothelin A Receptor AntagonistsPhase 340
12CitrateNutraceuticalPhase 3, Phase 1, Phase 21160
13
Citric Acidnutraceutical, vet_approvedPhase 3, Phase 1, Phase 2116077-92-9311
Synonyms:
2-Hydroxy-1,2,3-propanetricarboxylate
2-Hydroxy-1,2,3-propanetricarboxylic acid
2-Hydroxytricarballylic acid
3-Carboxy-3-hydroxypentane-1,5-dioate
3-Carboxy-3-hydroxypentane-1,5-dioic acid
Aciletten
Anhydrous citrate
Anhydrous citric acid
Chemfill
Citraclean
 
Citrate
Citretten
Citric acid
Citro
Citronensäure
E 330
Hydrocerol A
Kyselina citronova
Suby G
Uro-trainer
beta-Hydroxytricarballylate
beta-Hydroxytricarballylic acid
14
MilrinoneapprovedPhase 1, Phase 23578415-72-24197
Synonyms:
-bipyridine)-5-carbonitrile
1,6-Dihydro-2-methyl-6-oxo(3,4'-bipyridine)-5-carbonitrile
1,6-Dihydro-2-methyl-6-oxo-(3,4&prime
1,6-Dihydro-2-methyl-6-oxo-(3,4'-bipyridine)-5-carbonitrile
1,6-Dihydro-2-methyl-6-oxo-3,4-bipyridine-5-carbonitrile
1,6-Dihydro-2-methyl-6-oxo-[3,4'-bipyridine]-5-carbonitrile
111GE027
2-methyl-6-oxo-1,6-dihydro-3,4'-bipyridine-5-carbonitrile
3-Cyano-6-methyl-5-(4-pyridyl)-2-pyridone
6-Methyl-5-(4-pyridyl)-2-pyridone-3-carbonitrile
6-methyl-2-oxo-5-pyridin-4-yl-1H-pyridine-3-carbonitrile
78415-72-2
AB00514027
AC-4730
AC1L1HMP
AC1Q2EBX
BIDD:GT0197
BPBio1_001156
BRN 3546821
BSPBio_001050
C07224
C12H9N3O
CAS-78415-72-2
CCRIS 3795
CHEBI:50693
CHEMBL189
CID4197
CPD000058475
Corotrop
Corotrope
D00417
DB00235
EINECS 278-903-6
EN002063
EU-0100737
HMS1571E12
HMS2051L10
HMS2090J14
I06-0259
LS-44610
Lopac-M-4659
Lopac0_000737
 
M 4659
M1663
M4659_SIGMA
MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER
MLS000028818
MLS001424052
Milrila
Milrila (TN)
Milrinona
Milrinona [Spanish]
Milrinone
Milrinone (JAN/USAN/INN)
Milrinone Lactate
Milrinone [USAN:BAN:INN]
Milrinonum
Milrinonum [Latin]
NCGC00015675-01
NCGC00015675-02
NCGC00015675-04
NCGC00015675-07
NCGC00025189-01
NCGC00025189-02
NCGC00025189-03
NCGC00164390-01
PRIMACOR IN DEXTROSE 5% IN PLASTIC CONTAINER
Prestwick0_001065
Prestwick1_001065
Prestwick2_001065
Prestwick3_001065
Primacor
S2484_Selleck
SAM001246611
SBB055743
SMR000058475
SPBio_002965
Tocris-1504
UNII-JU9YAX04C7
WIN 47203-2
Win-47203
Win-47203-2
YM 018
ZINC09224016
milrinone
15
Tadalafilapproved, investigationalPhase 2155171596-29-5110635
Synonyms:
(6R,12AR)-2,3,6,7,12,12a-hexahydro-2-methyl-6-(3,4-(methylenedioxy)phenyl) pyrazino(1',2':1,6)pyrido(3,4-b)indole-1,4-dione
(6R,12aR)-2,3,6,7,12,12a-Hexahydro-2-methyl-6-(3,4-(methylenedioxy)phenyl) pyrazino(1',2':1,6)pyrido(3,4-b)indole-1,4-dione
(6R,12aR)-2,3,6,7,12,12a-Hexahydro-2-methyl-6-(3,4-methylenedioxyphenyl)pyrazino(1',2':1,6)pyrido(3,4-b)indole-1,4-dione
(6R-trans)-6-(1,3-Benzodioxol-5-yl)-2,3,6,7,12,12a-hexahydro-2-methyl-pyrazino(1',2':1,6)pyrido(3,4-b)indole-1,4-dione
171596-29-5
1xoz
6-BENZO[1,3]dioxol-5-yl-2-methyl-2,3,6,7,12,12a-hexahydro-pyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4-dione
AC1L380B
ADCIRCA
Acdirca
Adcirca
C429886
CHEBI:41488
CHEMBL779
CID110635
CPD000466321
Cialis
Cialis (TN)
Cialis, GF 196960, IC 351, ICOS 351, Tadalafil
D02008
DB00820
FT-0080116
GF 196960
GF-196960
 
HMS2051N17
HSDB 7303
IC 351
IC-351
ICOS 351
Ic351
KS-1117
LS-186558
LS-187015
LS-187770
Lilly brand of tadalafil
MLS000759426
MLS001165782
MLS001195644
MLS001424132
MolPort-002-885-864
S1512_Selleck
SAM001246586
SMR000466321
Tadalafil
Tadalafil (JAN/USAN/INN)
Tadalafil [USAN]
Tadanafil
UNII-742SXX0ICT
ZINC03993855
16Protective AgentsPhase 1, Phase 27443
17Phosphodiesterase 3 InhibitorsPhase 1, Phase 2133
18
Treprostinilapproved, investigational9181846-19-754786, 6918140
Synonyms:
((1R,2R,3aS,9aS)-2-hydroxy-1-((3S)-3-hydroxyoctyl)-2,3,3a,4,9,9a-hexahydro-1H-cylopent(b)naphthalen-5-yl)oxy)acetate
(1R,2R,3aS,9aS)-[[2,3,3a,4,9,9a-hexahydro-2-hydroxy- 1-[(3S)-3-hydroxyoctyl]-1H-benz[f]inden-5-yl] oxy]acetic acid
({(1R,2R,3aS,9aS)-2-hydroxy-1-[(3S)-3-hydroxyoctyl]-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]naphthalen-5-yl}oxy)acetic acid
15 AU81
15AU81
2-[[(1R,2R,3aS,9aS)-2-hydroxy-1-[(3S)-3-hydroxyoctyl]-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[g]naphthalen-5-yl]oxy]acetic acid
2-[[(1S,2S,3aR,9aR)-2-hydroxy-1-[(3R)-3-hydroxyoctyl]-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[g]naphthalen-5-yl]oxy]acetic acid
289480-64-4 (Sodium salt)
81846-19-7
AC1L1HPX
AC1OCF2J
CHEBI:50861
CID11246284
CID54786
CID6918140
CID9800580
D06213
DB00374
L001079
 
LRX 15
LS-177654
LS-187014
LS-187645
Remodulin (TN)
Treprostinil
Treprostinil (USAN/INN)
Treprostinil [USAN:INN]
Treprostinil sodium
Treprostinilo
Treprostinilum
U 62840
U-62,840
UNII-RUM6K67ESG
UT-15
Uniprost
Viveta
[[(1R,2R,3aS,9aS)-2-Hydroxy-1-[(3S)-3-hydroxyoctyl]-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]naphtalen-5-yl]oxy]acetic acid
treprostinilo
treprostinilum
19Selexipagapproved15475086-01-2
20
Epoprostenolapproved5461849-14-7, 35121-78-95280427, 5282411
Synonyms:
(5E)-5-[(3aR,4R,5R,6aS)-5-hydroxy-4-[(E,3R)-3-hydroxyoct-1-enyl]-3,3a,4,5,6,6a-hexahydrocyclopenta[b]furan-2-ylidene]pentanoic acid
(5Z)-5-[(3aR,4R,5R,6aS)-5-hydroxy-4-[(E,3S)-3-hydroxyoct-1-enyl]-3,3a,4,5,6,6a-hexahydrocyclopenta[b]furan-2-ylidene]pentanoic acid
(5Z)-5-[(4R,5R)-5-hydroxy-4-[(E,3S)-3-hydroxyoct-1-enyl]-3,3a,4,5,6,6a-hexahydrocyclopenta[b]furan-2-ylidene]pentanoic acid
(5Z,13E)-(15S)-6,9-alpha-epoxy-11-alpha,15-dihydroxyprosta-5,13-dienoate
(5Z,13E)-(15S)-6,9-alpha-epoxy-11-alpha,15-dihydroxyprosta-5,13-dienoic acid
(5Z,13E)-(15S)-6,9-epoxy-11,15-dihydroxyprosta-5,13-dienoate
(5Z,13E)-(15S)-6,9-epoxy-11,15-dihydroxyprosta-5,13-dienoic acid
(5Z,13E)-(15S)-6,9alpha-Epoxy-11alpha,15-dihydroxyprosta-5,13-dienoate
(5Z,13E)-(15S)-6,9alpha-Epoxy-11alpha,15-dihydroxyprosta-5,13-dienoic acid
(5Z,13E,15S)-6,9a-epoxy-11a,15-dihydroxyprosta-5,13-dienoate
(5Z,13E,15S)-6,9a-epoxy-11a,15-dihydroxyprosta-5,13-dienoic acid
(5Z,13E,15S)-6,9alpha-epoxy-11alpha,15-dihydroxyprosta-5,13-dienoic acid
(5Z,13e)-(15S)-6,9alpha-Epoxy-11alpha,15-dihydroxyprosta-5,13-dienoate
(5Z,9a,11a,13E,15S)-6,9-epoxy-11,15-dihydroxyprosta-5,13-dien-1-oate
(5Z,9a,11a,13E,15S)-6,9-epoxy-11,15-dihydroxyprosta-5,13-dien-1-oic acid
(5Z,9alpha,11alpha,13E,15S)-11,15-dihydroxy-6,9-epoxyprosta-5,13-dien-1-oic acid
(5Z,9alpha,11alpha,13E,15S)-6,9-epoxy-11,15-dihydroxyprosta-5,13-dien-1-oate
(5Z,9alpha,11alpha,13E,15S)-6,9-epoxy-11,15-dihydroxyprosta-5,13-dien-1-oic acid
(5Z,9alpha,11alpha,13e,15S)-6,9-Epoxy-11,15-dihydroxyprosta-5,13-dien-1-oic acid
(Z)-(3aR,4R,5R,6aS)-Hexahydro-5-hydroxy-4-((E)-(3S)-3-hydroxy-1-octenyl)-2H-cyclopenta(b)furan-delta(sup 2,delta)-valeric acid
136626-78-3
35121-78-9
5-[(3aR,4R,5R,6aS)-5-hydroxy-4-[(3S)-3-hydroxyoct-1-enyl]-3,3a,4,5,6,6a-hexahydrocyclopenta[b]furan-2-ylidene]pentanoic acid
5-[(3aR,4R,5R,6aS)-5-hydroxy-4-[(E,3S)-3-hydroxyoct-1-enyl]-3,3a,4,5,6,6a-hexahydrocyclopenta[b]furan-2-ylidene]pentanoic acid
5-[5-hydroxy-4-(3-hydroxyoct-1-enyl)-3,3a,4,5,6,6a-hexahydrocyclopenta[b]furan-2-ylidene]pentanoic acid
6,9-alpha-Epoxy-11-alpha,15(S)-dihydroxyprosta-5(Z),13(E)-dien-1-oic acid
61849-14-7
63748-50-5
63859-31-4
AC1L18LX
AC1L3FZB
AC1NQX0K
AC1NR00P
AC1O51WG
AC1O5HI7
AR-1I7150
BIDD:GT0514
BRD-K64054020-001-02-7
BRN 1690090
BSPBio_001496
Bio2_000216
Bio2_000696
C01312
CHEBI:15552
CHEMBL1139
CHEMBL307845
CID114805
CID11969614
CID159
CID5280427
CID5282411
CID6434194
CID6450541
 
CID9864371
CID9975312
D00106
DB01240
Epoprostanol
Epoprostenol
Epoprostenol (TN)
Epoprostenol (USAN/INN)
Epoprostenol [USAN:INN]
Epoprostenolum
Epoprostenolum [INN-Latin]
Flolan
HMS1791K18
HMS1989K18
IDI1_033966
KB-IV-24
KBio2_000216
KBio2_002784
KBio2_005352
KBio3_000431
KBio3_000432
KBioGR_000216
KBioSS_000216
LMFA03010087
LS-125828
NCGC00161285-01
NCGC00161285-02
NCGC00161285-03
PDSP1_001721
PDSP2_001704
PG-I2
PGI(sub 2)
PGI2
PGX
Prostacyclin
Prostacyclin I2
Prostacycline
Prostacyclins
Prostaglandin I
Prostaglandin I(2)
Prostaglandin I2
Prostaglandin X
Prostaglandin x
Prostaglandins X
SMP2_000227
TRY 200
Try-200
U 53,217
U-53217
UNII-DCR9Z582X0
Vasocyclin
epoprostenol
prostacyclin
prostaglandin I2
21
Ironapproved11657439-89-623925
Synonyms:
02583_FLUKA
12310_ALDRICH
12310_RIEDEL
129048-51-7
14067-02-8
161135-39-3
190454-13-8
195161-83-2
199281-22-6
209309_ALDRICH
209309_SIAL
255637_ALDRICH
266213_ALDRICH
266256_ALDRICH
267945_ALDRICH
267953_ALDRICH
26Fe
338141_ALDRICH
356808_ALDRICH
356824_ALDRICH
356832_ALDRICH
39344-71-3
3ZhP
413054_ALDRICH
443783-52-6
44890_ALDRICH
44890_FLUKA
675141-17-0
70884-35-4
73135-38-3
7439-89-6
8011-79-8
8053-60-9
AC1L2N38
ATW 230
ATW 432
Ancor B
Ancor en 80/150
Armco iron
Atomel 28
Atomel 300M200
Atomel 500M
Atomel 95
Atomiron 44MR
Atomiron 5M
Atomiron AFP 25
Atomiron AFP 5
C00023
C3518_SIAL
C3518_SIGMA
CCRIS 1580
CHEBI:18248
CID23925
Carbonyl iron
Copy Powder CS 105-175
D007501
DB01592
DSP 1000
DSP 128B
DSP 135
DSP 135C
DSP 138
Diseases (animal), iron overload
Diseases, iron overload
EF 1000
EF 250
EFV 200/300
EFV 250
EFV 250/400
EINECS 231-096-4
 
Ed-In-Sol
Eisen
Electrolytic iron
F 60 (metal)
FE
FT 3 (element)
Fe
Fe-40
Fe1+
Feronate
Ferretts
Ferro-Caps
Ferro-Time
Ferrousal
Ferrovac E
Ferrum
Ferrum metallicum
GS 6
HF 2 (element)
HL (iron)
HQ (metal)
HS (iron)
HS 4849
HSDB 604
Hemocyte
Hierro
Hoeganaes ATW 230
Hoeganaes EH
IRMM524A_FLUKA
IRMM524B_FLUKA
IRON
Iron (Fe)
Iron (Fe1+)
Iron ion (Fe+)
Iron ion(1+)
Iron monocation
Iron powder
Iron standard for AAS
Iron(1+)
Iron(1+) ion
Iron(III) nitrate solution
Iron, carbonyl
Iron, electrolytic
Iron, elemental
Iron, ion (Fe1+)
Iron, ion (Fe1+) (8CI,9CI)
Iron, reduced
LOHA
LS-3196
MolPort-003-925-001
NC 100
PZh-1M3
PZh-2
PZh1M1
PZh2M
PZh2M1
PZh2M2
PZh3
PZh3M
PZh4M
PZhO
Reduced iron
Remko
SUY-B 2
Siderol
UNII-E1UOL152H7
Vitedyn-Slo
Yieronia
fer
ferrous iron
hierro
22
Allopurinolapproved145315-30-02094
Synonyms:
1,5-Dihydro-4H-pyrazolo(3,4-D)pyrimidin-4-one
1,5-Dihydro-4H-pyrazolo(3,4-D)pyrimidine-4-one
184856-42-6
1H-Pyrazolo(3,4-D)pyrimidin-4-ol
22767-92-6
315-30-0
39464-14-7
4'-Hydroxypyrazolol(3,4-D)pyrimidine
4-HPP
4-Hydroxy-1H-pyrazolo(3,4-D)pyrimidine
4-Hydroxy-3,4-pyrazolopyrimidine
4-Hydroxypyrazolo(3,4-D)pyrimidine
4-Hydroxypyrazolopyrimidine
4-Hydroxypyrazolyl(3,4-D)pyrimidine
4H-Pyrazolo(3,4-D)pyrimidin-4-one
7HP
A 8003
A0907
A8003_SIGMA
AC-019
AC1L1CWL
AC1Q6FWV
AC1Q6GP7
AKOS000267490
AKOS000269759
AL-100
Adenock
Ailural
Ailurial
Allo-Puren
Allohexal
Allohexan
Alloprin
Allopur
Allopurin
Allopurinol
Allopurinol Sodium
Allopurinol(I)
Allopurinolum
Allopurinolum [INN-Latin]
Allorin
Allozym
Allpargin
Allural
Aloprim
Alopurinol
Alopurinol [INN-Spanish]
Aloral
Alositol
Aluline
Anoprolin
Anzief
Apo-Allopurinol
Apulonga
Apurin
Apurol
Atisuril
B. W. 56-158
BB_SC-5394
BIM-0061756.0001
BSPBio_001798
BW 56-158
BW 56158
BW-56-158
Bio-0799
Bleminol
Bloxanth
C5H4N4O
CCRIS 626
CHEBI:40279
CHEBI:495607
CHEMBL1467
CID2094
CPD-9024
CPD000059083
Caplenal
Capurate
Cellidrin
Cosuric
D000493
DB00437
Dabrosin
Dabroson
DivK1c_000685
Dura Al
EINECS 206-250-9
EN000932
EU-0100102
Embarin
Epidropal
Epuric
Foligan
Geapur
Gichtex
Gotax
HMS1920A15
HMS2091G15
HMS502C07
HPP
 
HSDB 3004
Hamarin
Hexanuret
I03-0052
IDI1_000685
Jenapurinol
Jsp005881
KBio1_000685
KBio2_000386
KBio2_002954
KBio2_005522
KBio3_001298
KBioGR_000550
KBioSS_000386
Ketanrift
Ketobun-A
LS-1180
Ledopur
Lopac-A-8003
Lopac0_000102
Lopurin
Lysuron
MLS000069453
MLS001148183
Milurit
Milurite
Miniplanor
MolPort-000-141-383
MolPort-000-870-337
MolPort-004-758-159
MolPort-004-758-166
MolPort-004-758-167
MolPort-004-758-643
Monarch
NCGC00015094-01
NCGC00015094-03
NCGC00015094-06
NCGC00091134-01
NCGC00091134-02
NCGC00091134-03
NCGC00094580-01
NCGC00094580-02
NCIOpen2_001825
NINDS_000685
NSC 101655
NSC 1390
NSC-1390
NSC101655
NSC1390
Nektrohan
Novopurol
Pan Quimica
Prestwick_511
Progout
Pureduct
Purinol
Quimica, Pan
Remid
Riball
Rimapurinol
Roucol
S1630_Selleck
SAM002554884
SMR000059083
SPBio_000056
SPECTRUM1500108
STK378584
STK711106
Sigapurol
Spectrum2_000098
Spectrum3_000289
Spectrum4_000135
Spectrum5_000768
Spectrum_000026
Suspendol
Takanarumin
Tipuric
UNII-63CZ7GJN5I
Urbol
Uribenz
Uricemil
Uridocid
Uriprim
Uripurinol
Uritas
Urobenyl
Urolit
Urosin
Urtias
Urtias 100
Xanthomax
Xanturat
Xanturic
Zygout
Zyloprim
Zyloprim (tn)
Zyloric
allopurinol
nchembio.92-comp3
nchembio732-comp4
23Imatinib Mesylate600123596
24Vaccines6611
25diuretics1418
26Anticoagulants2623
27Anti-Bacterial Agents11226
28Antibiotics, Antitubercular7180
29Angiotensin-Converting Enzyme Inhibitors724
30Tezosentan64

Interventional clinical trials:

(show all 22)
idNameStatusNCT IDPhase
1Effects of Iloprost Treatment in Adult Patients With Pulmonary Arterial Hypertension Related to Congenital Heart DiseaseUnknown statusNCT01383083Phase 4
2Effects of Tracleer (Bosentan) on Pulmonary Arterial Hypertension Related to Eisenmenger PhysiologyCompletedNCT00317486Phase 4
3BREATHE 5-OL: Tracleer (Bosentan) in Patients With Pulmonary Arterial Hypertension Related to Eisenmenger PhysiologyCompletedNCT00367770Phase 4
4Bosentan in Treatment of Pulmonary Arterial HypertensionCompletedNCT00266162Phase 4
5Combination Treatment With Bosentan and Sildenafil to Patients With Eisenmengers SyndromeCompletedNCT00303004Phase 3
6Clinical Study to Evaluate the Effects of Macitentan on Exercise Capacity in Subjects With Eisenmenger SyndromeCompletedNCT01743001Phase 3
7Clinical Study to Assess the Long-term Safety, Tolerability, and Efficacy of Macitentan in Subjects With Eisenmenger SyndromeActive, not recruitingNCT01739400Phase 3
8Therapy of Pulmonary Arterial Hypertension (PAH) - Treatment With Sildenafil in Eisenmenger PatientsTerminatedNCT00586794Phase 3
9Respiratory and Physical Therapy in Patients With Associated Pulmonary Arterial Hypertension (APAH) With Congenital Heart DefectsUnknown statusNCT01397110Phase 2
10Phosphodiesterase-5 Inhibitor in Eisenmenger SyndromeCompletedNCT01200732Phase 2
11Oral Sildenafil and Intravenous Milrinone on Postoperative Pulmonary HypertensionCompletedNCT02595541Phase 1, Phase 2
12Exercise Capacity and Quality of Life in Patients With PPH Receiving Short Term Oral L-Citrulline MalateUnknown statusNCT01683981Early Phase 1
13The Effects of Inhaled Iloprost on Congenital Heart Disease With Eisenmenger SyndromeCompletedNCT01283958
14Effects Oxygen Supplementation Determined Better Exercise Capacity in Eisenmenger SyndromeCompletedNCT02661802
15Sleep-disordered Breathing in Eisenmenger SyndromeCompletedNCT02614417
16Eisenmenger's Syndrome in Adults With CHDCompletedNCT00266903
17Six Minutes Walk Test and Shuttle Walk Test in Eisenmenger SyndromeRecruitingNCT02752399
18Transcatheter Valve Implantation in Patients With Dysfunctional Left and Right Sided Heart ValvesRecruitingNCT02119442
19COMPERA / COMPERA-KIDSRecruitingNCT01347216
20Eisenmenger Quality Enhancement Research InitiativeActive, not recruitingNCT01623492
21Eisenmenger Syndrome in the Nordic CountriesActive, not recruitingNCT01976533
22Iloprost for the Treatment of Pulmonary Hypertension in Adults With Congenital Heart DiseaseTerminatedNCT01319045

Search NIH Clinical Center for Eisenmenger Syndrome

Genetic Tests for Eisenmenger Syndrome

About this section

Anatomical Context for Eisenmenger Syndrome

About this section

MalaCards organs/tissues related to Eisenmenger Syndrome:

36
Heart, Lung, Brain, Endothelial, Breast, Testes

Publications for Eisenmenger Syndrome

About this section

Articles related to Eisenmenger Syndrome:

(show top 50)    (show all 258)
idTitleAuthorsYear
1
Brain metabolite alterations in Eisenmenger syndrome: Evaluation with MR proton spectroscopy. (28027769)
2017
2
Effects of acute oxygen supplementation on functional capacity and heart rate recovery in Eisenmenger syndrome. (28082094)
2017
3
Platelet abnormalities in adults with severe pulmonary arterial hypertension related to congenital heart defects (Eisenmenger syndrome). (26829363)
2016
4
Assessment of the Physiological Adaptations to Chronic Hypoxemia in Eisenmenger Syndrome. (27198869)
2016
5
Electrocardiogram in a Young Woman With the Eisenmenger Syndrome. (27287060)
2016
6
Effects of long-term iloprost treatment on right ventricular function in patients with Eisenmenger syndrome. (27492657)
2016
7
Case 1/2016 - 56-Year-Old Male with Atrial Septal Defect, Pulmonary Arterial Hypertension, Hospitalized Due to Eisenmenger Syndrome. (27027369)
2016
8
Long-term outcomes of pulmonary arterial hypertension under specific drug therapy in Eisenmenger syndrome. (27866929)
2016
9
Brain diffusion changes in Eisenmenger syndrome. (27767324)
2016
10
Current therapy and outcome of Eisenmenger syndrome: data of the German National Register for congenital heart defects. (26843280)
2016
11
Speckle-tracking imaging in patients with Eisenmenger syndrome. (26868160)
2016
12
Eisenmenger syndrome and long-term survival in patients with Down syndrome and congenital heart disease. (27325590)
2016
13
Eisenmenger syndrome in an adult patient with aortopulmonary window. (27727969)
2016
14
Eisenmenger Syndrome in Pregnancy. (27849306)
2016
15
OS 12-06 EFFECT OF LONG-TERM ILOPROST TREATMENT ON THE RIGHT VENTRICULAR FUNCTION IN PATIENTS WITH EISENMENGER SYNDROME. (27753979)
2016
16
18F-FDG PET/CT in a Patient With Glomus Vagale Paraganglioma and Eisenmenger Syndrome: Searching for the Missing Link? (26673238)
2016
17
Advanced Therapy in Eisenmenger Syndrome - A Systematic Review. (27054605)
2016
18
Sleep-disordered breathing in Eisenmenger Syndrome. (27055162)
2016
19
Preoperative Assessment of the Impact of Positive Pressure Ventilation With Noninvasive Positive Pressure Ventilation in a Patient With Eisenmenger Syndrome: A Case Study. (27552240)
2016
20
Cardiac remodelling amongst adults with various aetiologies of pulmonary arterial hypertension including Eisenmenger syndrome-implications on survival and the role of right ventricular transverse strain. (28011668)
2016
21
OS 12-06 EFFECT OF LONG-TERM ILOPROST TREATMENT ON THE RIGHT VENTRICULAR FUNCTION IN PATIENTS WITH EISENMENGER SYNDROME. (27643376)
2016
22
Anaesthetic management of breast surgery in a patient with Eisenmenger syndrome. (27554331)
2016
23
Sinus Venosus Atrial Septal Defect Complicated by Eisenmenger Syndrome and the Role of Vasodilator Therapy. (27974976)
2016
24
Predictors of Death in Contemporary Adult Patients with Eisenmenger Syndrome: A Multicentre Study. (27979875)
2016
25
Giant retroperitoneal cystic lymphangioma in a patient with Eisenmenger syndrome. (26590885)
2016
26
An intra-cerebral abscess in a patient with Eisenmenger syndrome: An unusual case. (26859871)
2016
27
Current therapy of Eisenmenger syndrome. (28066570)
2016
28
Pulmonary Hypertension in Congenital Heart Disease: Beyond Eisenmenger Syndrome. (26471823)
2015
29
Oxygen Desaturation During Drainage of Brain Abscess in Prone Position in a Child With Eisenmenger Syndrome. (26397236)
2015
30
Clinical and Prognostic Value of Depressive Symptoms and N-Terminal Pro-B-Type Natriuretic Peptide in Patients With Eisenmenger Syndrome. (26355727)
2015
31
Medical treatment for an adult patient with eisenmenger syndrome. (25787798)
2015
32
First description of successful weaning from ECMO in a patient with Eisenmenger syndrome after repair of pulmonary artery dissection. (25828338)
2015
33
Pulmonary arterial wall thickness in Eisenmenger Syndrome: Prospective, cross-sectional, controlled clinical trial. (26110269)
2015
34
Eisenmenger syndrome with unrepaired patent ductus arteriosus. (25901073)
2015
35
Physiological differences between various types of Eisenmenger syndrome and relation to outcome. (25465305)
2015
36
The Sophistication of Simplicity: Ventricular Function and Oximetry Predict Survival in Eisenmenger Syndrome. (26659368)
2015
37
Update on medical treatment of patients with eisenmenger syndrome. (25787797)
2015
38
Catecholamine-secreting paraganglioma in a patient with Eisenmenger syndrome and a single ventricle. Nitric oxide administration and minimally invasive haemodynamic monitoring. (26235172)
2015
39
Incidentally detected right-to-left intracardiac shunt with Eisenmenger syndrome on V/Q SPECT/CT. (25573810)
2015
40
Impaired Right, Left, or Biventricular Function and Resting Oxygen Saturation Are Associated With Mortality in Eisenmenger Syndrome: A Clinical and Cardiovascular Magnetic Resonance Study. (26659374)
2015
41
Pulmonary arterial hypertension associated with congenital heart disease and Eisenmenger syndrome: current practice in pediatrics. (25604592)
2015
42
Perioperative Care of Children with Eisenmenger Syndrome Undergoing Non-cardiac Surgery. (25958153)
2015
43
Aortopulmonary Window and Interrupted Aortic Arch With Eisenmenger Syndrome in an Adult. (26416632)
2015
44
Life span of patients with Eisenmenger syndrome is not superior to that of patients with other causes of pulmonary hypertension. (25414820)
2014
45
Pulmonary hypertensive vascular changes in lungs of patients with sudden unexpected death. Emphasis on congenital heart disease, Eisenmenger syndrome, postoperative deaths and death during pregnancy and postpartum. (25342758)
2014
46
Pulmonary hypertension in adults with congenital heart disease and Eisenmenger syndrome: current advanced management strategies. (24829371)
2014
47
P-wave and QT interval dispersion analysis in children with Eisenmenger syndrome. (24643147)
2014
48
Oral l-citrulline malate in patients with idiopathic pulmonary arterial hypertension and Eisenmenger Syndrome: a clinical trial. (24525046)
2014
49
Lung function and gas exchange in Eisenmenger syndrome and their impact on exercise capacity and survival. (24331639)
2014
50
Repair of ventricular septal defect with Eisenmenger syndrome after bosentan treatment. (24612361)
2014

Variations for Eisenmenger Syndrome

About this section

Expression for genes affiliated with Eisenmenger Syndrome

About this section
Search GEO for disease gene expression data for Eisenmenger Syndrome.

Pathways for genes affiliated with Eisenmenger Syndrome

About this section

Pathways related to Eisenmenger Syndrome according to GeneCards Suite gene sharing:

(show all 43)
idSuper pathwaysScoreTop Affiliating Genes
19.6TGFBR1, TGFBR2
2
Show member pathways
9.2TGFBR1, TGFBR2, TGFBR3
39.2TGFBR1, TGFBR2, TGFBR3
4
Show member pathways
9.2PLAT, THBD, VWF
5
Show member pathways
9.2PLAT, THBD, VWF
69.1BMPR2, TGFBR1, TGFBR2
7
Show member pathways
8.8EDN1, TGFB1, TGFBR1
8
Show member pathways
8.8TGFB1, TGFBR1, TGFBR2
9
Show member pathways
8.8TGFB1, TGFBR1, TGFBR2
108.8TGFB1, TGFBR1, TGFBR2
11
Show member pathways
8.8TGFB1, TGFBR1, TGFBR2
12
Show member pathways
8.8TGFB1, TGFBR1, TGFBR2
13
Show member pathways
8.8TGFB1, TGFBR1, TGFBR2
14
Show member pathways
8.8TGFB1, TGFBR1, TGFBR2
158.8TGFB1, TGFBR1, TGFBR2
16
Show member pathways
8.8TGFB1, TGFBR1, TGFBR2
17
Show member pathways
8.8TGFB1, TGFBR1, TGFBR2
188.8TGFB1, TGFBR1, TGFBR2
198.8TGFB1, TGFBR1, TGFBR2
208.8TGFB1, TGFBR1, TGFBR2
21
Show member pathways
8.8TGFB1, TGFBR1, TGFBR2
22
Show member pathways
8.6TGFB1, TGFBR1, TGFBR3, VWF
238.6BMPR2, EDN1, PLAT, THBD
248.5BMPR2, TGFB1, TGFBR1, TGFBR3
258.4TGFB1, TGFBR1, TGFBR2, TGFBR3
268.4TGFB1, TGFBR1, TGFBR2, TGFBR3
27
Show member pathways
8.4TGFB1, TGFBR1, TGFBR2, TGFBR3
288.4TGFB1, TGFBR1, TGFBR2, TGFBR3
29
Show member pathways
8.4TGFB1, TGFBR1, TGFBR2, TGFBR3
30
Show member pathways
8.4TGFB1, TGFBR1, TGFBR2, TGFBR3
31
Show member pathways
8.4TGFB1, TGFBR1, TGFBR2, TGFBR3
32
Show member pathways
8.4TGFB1, TGFBR1, TGFBR2, TGFBR3
33
Show member pathways
8.3BMPR2, TGFB1, TGFBR1, TGFBR2
34
Show member pathways
8.3BMPR2, TGFB1, TGFBR1, TGFBR2
35
Show member pathways
8.3BMPR2, TGFB1, TGFBR1, TGFBR2
368.3BMPR2, TGFB1, TGFBR1, TGFBR2
37
Show member pathways
8.3BMPR2, TGFB1, TGFBR1, TGFBR2
38
Show member pathways
8.1PLAT, TGFB1, TGFBR1, TGFBR2
39
Show member pathways
8.0BMPR2, TGFB1, TGFBR1, TGFBR2, TGFBR3
407.9EDN1, TGFB1, TGFBR1, TGFBR2, THBD
41
Show member pathways
7.9EDN1, TGFB1, TGFBR1, TGFBR2, TGFBR3
427.8PLAT, TGFB1, TGFBR1, TGFBR2, TGFBR3
43
Show member pathways
6.4BMPR2, EDN1, PLAT, TGFB1, TGFBR1, TGFBR2

GO Terms for genes affiliated with Eisenmenger Syndrome

About this section

Cellular components related to Eisenmenger Syndrome according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1transforming growth factor beta receptor complexGO:00700229.7TGFBR1, TGFBR2
2Weibel-Palade bodyGO:00330939.6EDN1, VWF
3receptor complexGO:00432359.5TGFBR1, TGFBR2, TGFBR3
4extracellular spaceGO:00056158.0BMPR2, EDN1, PLAT, TGFB1, TGFBR3, THBD
5cell surfaceGO:00099867.8BMPR2, PLAT, TGFB1, TGFBR1, TGFBR2, TGFBR3

Biological processes related to Eisenmenger Syndrome according to GeneCards Suite gene sharing:

(show all 48)
idNameGO IDScoreTop Affiliating Genes
1cardiac epithelial to mesenchymal transitionGO:006031710.5TGFBR1, TGFBR3
2activin receptor signaling pathwayGO:003292410.4BMPR2, TGFBR1
3regulation of protein bindingGO:004339310.4TGFBR1, TGFBR3
4negative regulation of blood coagulationGO:003019510.4EDN1, THBD
5embryonic cranial skeleton morphogenesisGO:004870110.3TGFBR1, TGFBR2
6lens development in camera-type eyeGO:000208810.3TGFBR1, TGFBR2
7body fluid secretionGO:000758910.3EDN1, VIP
8positive regulation of epithelial to mesenchymal transition involved in endocardial cushion formationGO:190500710.3TGFBR1, TGFBR2
9ventricular compact myocardium morphogenesisGO:000322310.3TGFBR1, TGFBR3
10atrioventricular valve morphogenesisGO:000318110.3BMPR2, TGFBR2
11outflow tract septum morphogenesisGO:000314810.3BMPR2, TGFBR2
12positive regulation of epithelial cell migrationGO:001063410.2BMPR2, TGFBR2
13branching involved in blood vessel morphogenesisGO:000156910.2EDN1, TGFBR2
14tricuspid valve morphogenesisGO:000318610.1BMPR2, TGFBR2
15germ cell migrationGO:000835410.0TGFB1, TGFBR1
16positive regulation of SMAD protein import into nucleusGO:006039110.0TGFB1, TGFBR1
17blood coagulationGO:000759610.0PLAT, THBD, VWF
18palate developmentGO:006002110.0TGFBR1, TGFBR2, TGFBR3
19positive regulation of bone mineralizationGO:00305019.9BMPR2, TGFB1
20outflow tract morphogenesisGO:00031519.9BMPR2, TGFBR2, TGFBR3
21common-partner SMAD protein phosphorylationGO:00071829.9TGFB1, TGFBR2
22digestive tract developmentGO:00485659.9TGFB1, TGFBR2
23myeloid dendritic cell differentiationGO:00430119.9TGFB1, TGFBR2
24positive regulation of odontogenesisGO:00424829.9EDN1, TGFB1
25ventricular cardiac muscle tissue morphogenesisGO:00550109.9TGFB1, TGFBR3
26in utero embryonic developmentGO:00017019.8EDN1, TGFBR1, TGFBR2
27signal transduction by protein phosphorylationGO:00230149.7BMPR2, TGFBR1, TGFBR2
28epithelial to mesenchymal transitionGO:00018379.7TGFB1, TGFBR1, TGFBR3
29transmembrane receptor protein serine/threonine kinase signaling pathwayGO:00071789.7BMPR2, TGFBR1, TGFBR2
30BMP signaling pathwayGO:00305099.6BMPR2, TGFB1, TGFBR3
31animal organ regenerationGO:00311009.6TGFB1, TGFBR2, TGFBR3
32cell growthGO:00160499.6EDN1, TGFB1, TGFBR3
33positive regulation of pathway-restricted SMAD protein phosphorylationGO:00108629.6BMPR2, TGFB1, TGFBR1
34cellular response to transforming growth factor beta stimulusGO:00715609.5EDN1, TGFB1, TGFBR1
35positive regulation of cell migrationGO:00303359.5EDN1, TGFB1, TGFBR1
36positive regulation of epithelial to mesenchymal transitionGO:00107189.5TGFB1, TGFBR1, TGFBR2
37regulation of gene expressionGO:00104689.4TGFB1, TGFBR1, TGFBR2
38response to cholesterolGO:00707239.4TGFB1, TGFBR1, TGFBR2
39regulation of cell proliferationGO:00421279.4BMPR2, TGFB1, TGFBR2
40ventricular septum morphogenesisGO:00604129.3BMPR2, TGFBR1, TGFBR2, TGFBR3
41negative regulation of transforming growth factor beta receptor signaling pathwayGO:00305129.2TGFB1, TGFBR1, TGFBR2, TGFBR3
42pathway-restricted SMAD protein phosphorylationGO:00603899.2TGFB1, TGFBR1, TGFBR2, TGFBR3
43heart developmentGO:00075079.0EDN1, TGFB1, TGFBR1, TGFBR2
44protein phosphorylationGO:00064689.0BMPR2, TGFB1, TGFBR1, TGFBR2
45transforming growth factor beta receptor signaling pathwayGO:00071799.0TGFB1, TGFBR1, TGFBR2, TGFBR3
46wound healingGO:00420608.8TGFB1, TGFBR1, TGFBR2
47positive regulation of cell proliferationGO:00082848.6EDN1, TGFB1, TGFBR1, TGFBR2, VIP
48response to hypoxiaGO:00016668.3EDN1, PLAT, TGFB1, TGFBR2, TGFBR3

Molecular functions related to Eisenmenger Syndrome according to GeneCards Suite gene sharing:

(show all 10)
idNameGO IDScoreTop Affiliating Genes
1glycosaminoglycan bindingGO:000553910.4TGFBR2, TGFBR3
2SMAD bindingGO:00463329.7TGFBR1, TGFBR2, TGFBR3
3transforming growth factor beta bindingGO:00504319.6TGFBR1, TGFBR2, TGFBR3
4signal transducer, downstream of receptor, with serine/threonine kinase activityGO:00047029.6BMPR2, TGFBR1, TGFBR2
5transforming growth factor beta-activated receptor activityGO:00050249.6TGFBR1, TGFBR2, TGFBR3
6glycoprotein bindingGO:00019489.5PLAT, TGFB1, VWF
7transmembrane receptor protein serine/threonine kinase activityGO:00046759.4BMPR2, TGFBR1, TGFBR2
8type I transforming growth factor beta receptor bindingGO:00347139.3TGFB1, TGFBR2
9type II transforming growth factor beta receptor bindingGO:00051148.9TGFB1, TGFBR1, TGFBR3
10protein bindingGO:00055156.3BMPR2, EDN1, PLAT, TGFB1, TGFBR1, TGFBR2

Sources for Eisenmenger Syndrome

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
27GTR
28HGMD
29HMDB
30ICD10
31ICD10 via Orphanet
32ICD9CM
33IUPHAR
34KEGG
37MedGen
39MeSH
40MESH via Orphanet
41MGI
44NCI
45NCIt
46NDF-RT
49NINDS
50Novoseek
52OMIM
53OMIM via Orphanet
57PubMed
58QIAGEN
63SNOMED-CT via Orphanet
67Tumor Gene Family of Databases
68UMLS
69UMLS via Orphanet